Circulating Mitochondrial DNA is an Early Indicator of Severe Illness and Mortality from COVID-19

Davide Scozzi(Washington University in St. Louis), Marlene Cano(Washington University in St. Louis), Lina Ma(Washington University in St. Louis), Dequan Zhou(Washington University in St. Louis), Ji Hong Zhu(Washington University in St. Louis), Jane A. O’Halloran(Washington University in St. Louis), Charles Goss(Washington University in St. Louis), Adriana M. Rauseo(Washington University in St. Louis), Zhiyi Liu(Washington University in St. Louis), Valentina Peritore(Sapienza University of Rome), Monica Rocco(Sapienza University of Rome), Alberto Rícci(Sapienza University of Rome), Rachele Amodeo(Labor (Italy)), Laura Aimati(Labor (Italy)), Mohsen Ibrahim(Washington University in St. Louis), Ramsey R. Hachem(Washington University in St. Louis), Daniel Kreisel(Washington University in St. Louis), Philip A. Mudd(Washington University in St. Louis), Hrishikesh S. Kulkarni(Washington University in St. Louis), Andrew E. Gelman(Washington University in St. Louis)
bioRxiv (Cold Spring Harbor Laboratory)
July 30, 2020
Cited by 93Open Access
Full Text

Abstract

Mitochondrial DNA (MT-DNA) are intrinsically inflammatory nucleic acids released by damaged solid organs. Whether the appearance of cell-free MT-DNA is linked to poor COVID-19 outcomes remains undetermined. Here, we quantified circulating MT-DNA in prospectively collected, cell-free plasma samples from 97 subjects with COVID-19 at the time of hospital presentation. Circulating MT-DNA were sharply elevated in patients who eventually died, required ICU admission or intubation. Multivariate regression analysis revealed that high circulating MT-DNA levels is an independent risk factor for all of these outcomes after adjusting for age, sex and comorbidities. Additionally, we found that circulating MT-DNA has a similar or superior area-under-the curve when compared to clinically established measures of systemic inflammation, as well as emerging markers currently of interest as investigational targets for COVID-19 therapy. These results show that high circulating MT-DNA levels is a potential indicator for poor COVID-19 outcomes.


Related Papers

No related papers found

Powered by citation graph analysis